News Headlines Article

Amgen pleads guilty, to settle misbranding case for $762 million
Los Angeles Times

Biotech giant Amgen Inc. pleaded guilty to a federal misdemeanor of misbranding its anemia drug Aranesp and has agreed to pay $762 million in fines and penalties.

The Thousand Oaks company said it had reached a preliminary settlement of federal criminal and civil investigations last year and had already set aside about $780 million to resolve several related cases.

A spokesman for the U.S. attorney’s office in Brooklyn said a federal judge is scheduled to hold another hearing on the settlement Wednesday.

Commands